计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P129617-10mg |
10mg |
现货 ![]() |
| |
| P129617-50mg |
50mg |
现货 ![]() |
| |
| P129617-250mg |
250mg |
现货 ![]() |
| |
| P129617-1g |
1g |
现货 ![]() |
|
| 别名 | 匹伐他汀钙 |
|---|---|
| 英文别名 | (3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic acid hemicalcium salt | Itavastatin calcium | NK 104 | Q-201590 | PITAVASTATIN CALCIUM [ORANGE BOOK] | calcium bis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinoli |
| 规格或纯度 | ≥99% |
| 英文名称 | Pitavastatin Calcium |
| 生化机理 | Pitavastatin Calcium 是一种新型的Statins类药物。Potent, competitive inhibitor of HMG-CoA reductase (K i = 1.7nM). Blocks cholesterol synthesis. Displays cardioprotective properties. Orally active. |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | HMG-CoA 还原酶抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis. Alternate studies show that pitavastatin can suppress oxygen production in endothelial cells by inhibiting NADPH oxidase. In addition, pitavastatin reduces the expression of eNOS mRNA while increasing the NO dependent response stimulated by acetylcholine and the calcium ionophore, A23187. Furthermore, pitavastatin inhibits the up-regulation of conductance calcium-activated potassium channels by lowering cholesterol levels in cells.A competitive inhibitor of HMG-CoA reductase Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis. Alternate studies show that pitavastatin can suppress oxygen production in endothelial cells by inhibiting NADPH oxidase. In addition, pitavastatin reduces the expression of eNOS mRNA while increasing the NO dependent response stimulated by acetylcholine and the calcium ionophore, A23187. Furthermore, pitavastatin inhibits the up-regulation of conductance calcium-activated potassium channels by lowering cholesterol levels in cells. |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488195263 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | calcium;(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate |
| INCHI | 1S/2C25H24FNO4.Ca/c2*26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31;/h2*1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31);/q;;+2/p-2/b2*12-11+;/t2*18-,19-;/m11./s1 |
| InChi Key | RHGYHLPFVJEAOC-FFNUKLMVSA-L |
| Smiles | C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)[O-])O)O)C4=CC=C(C=C4)F.C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)[O-])O)O)C4=CC=C(C=C4)F.[Ca+2] |
| Isomeric SMILES | C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2] |
| 关联CAS | 147511-69-1 |
| PubChem CID | 5282451 |
| 分子量 | 880.98 |
| 溶解性 | DMSO 51 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 分子量 | 881.000 g/mol |
| XLogP3 | |
| 氢键供体数Hydrogen Bond Donor Count | 4 |
| 氢键受体数Hydrogen Bond Acceptor Count | 12 |
| 可旋转键计数Rotatable Bond Count | 14 |
| 精确质量Exact Mass | 880.285 Da |
| 单同位素质量Monoisotopic Mass | 880.285 Da |
| 拓扑极表面积Topological Polar Surface Area | 187.000 Ų |
| 重原子数Heavy Atom Count | 63 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 626.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 4 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 2 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 2 |
| 共价键合单元计数Covalently-Bonded Unit Count | 3 |
| 象形图 | GHS08 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H361f: 怀疑破坏生育力 |
| 预防措施声明 |
P201: 使用前获取特殊说明 P202: 在阅读并理解所有安全预防措施之前,不要进行操作。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P308+P313: 如接触到或有疑虑:求医/就诊。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 | |
| 分析证书 | P129617 |
| 1. Montonye ML et al.. (2019) A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model.. J Pharmacol Exp Ther, 371 (2): (385-393). [PMID:31420525] |
| 2. Paškeviciute M & Petrikaite V. (2017) Differences of statin activity in 2D and 3D pancreatic cancer cell cultures.. Drug Des Devel Ther, 11 (3273-3280). [PMID:29180851] |
| 3. Kolawole EM et al.. (2016) Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects.. J Immunol, 196 (4): (1461-70). [PMID:26773154] |
| 4. Lynch KD et al.. (2021) Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.. Phytother Res, 35 (6): (3286-3297). [PMID:33587330] |
| 5. Liu H et al.. (2017) Pitavastatin nanoparticle-engineered endothelial progenitor cells repair injured vessels.. Sci Rep, 7 (18067). [PMID:29273744] |